AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 37394382 — intervention group
Group type: EXPERIMENTAL
Intervention: Envarsus
Number of subjects: 100
Study 37394382 — intervention group
Group type: COMPARATOR
Intervention: Tacrolimus
Number of subjects: 100
Study 37394389 — intervention group
Group type: EXPERIMENTAL
Intervention: Adhesive P (containing MDPB)
Number of subjects: 5102
Study 37394389 — intervention group
Group type: COMPARATOR
Intervention: Adhesive S (control)
Number of subjects: 5102
Study 37394507 — intervention group
Group type: EXPERIMENTAL
Intervention: Saliva-delivered PCR COVID-19 test
Number of subjects: 227
Study 37394507 — intervention group
Group type: EXPERIMENTAL
Intervention: Saliva sampling for COVID-19
Number of subjects: 227
Study 37394507 — intervention group
Group type: EXPERIMENTAL
Intervention: Alternate testing strategies
Number of subjects: 227
Study 37394627 — intervention group
Group type: EXPERIMENTAL
Intervention: Adavosertib (225 mg bid) co-administration with cocktail
Number of subjects: 33
Study 37394739 — intervention group
Group type: EXPERIMENTAL
Intervention: Conversation-based decision aid containing information about low-risk prostate cancer management options and their relative costs.
Number of subjects: 117
Study 37394920 — intervention group
Group type: EXPERIMENTAL
Intervention: BMS-986141, a novel, oral, PAR4 agonist, administered as a single ascending dose.
Number of subjects: 0
Study 37394920 — intervention group
Group type: COMPARATOR
Intervention: Placebo (control group)
Number of subjects: 0
Study 37395048 — intervention group
Group type: EXPERIMENTAL
Intervention: CT total-airway-count (TAC) measurements
Number of subjects: 0
Study 37395048 — intervention group
Group type: EXPERIMENTAL
Intervention: Airway wall-thickness measurements
Number of subjects: 0
Study 37395101 — intervention group
Group type: EXPERIMENTAL
Intervention: Collaborative care (CC)
Number of subjects: 691
Study 37395101 — intervention group
Group type: COMPARATOR
Intervention: Consultation liaison (CL)
Number of subjects: 691
Study 37395169 — intervention group
Group type: EXPERIMENTAL
Intervention: Transcutaneous magnetic stimulation (TCMS) applied to each foot once a week for four weeks (n=18)
Number of subjects: 34
Study 37395169 — intervention group
Group type: COMPARATOR
Intervention: Sham treatment applied to each foot once a week for four weeks (n=16)
Number of subjects: 34
Study 37395185 — intervention group
Group type: EXPERIMENTAL
Intervention: Activated recombinant FVII (rFVIIa) at a recommended dose of 15-30 μg/kg
Number of subjects: 20
Study 37395254 — intervention group
Group type: EXPERIMENTAL
Intervention: Tenofovir disoproxil fumarate (TDF)
Number of subjects: 2
Study 37395254 — intervention group
Group type: EXPERIMENTAL
Intervention: Etravirine (ETR)
Number of subjects: 2
Study 37395254 — intervention group
Group type: EXPERIMENTAL
Intervention: Integrase-strand transfer inhibitors (INSTIs)
Number of subjects: 2
Study 37395286 — intervention group
Group type: EXPERIMENTAL
Intervention: Watchful waiting (WW) patients
Number of subjects: 313
Study 37395286 — intervention group
Group type: EXPERIMENTAL
Intervention: Endovascular aneurysm repair (EVAR) patients
Number of subjects: 313
Study 37395501 — intervention group
Group type: EXPERIMENTAL
Intervention: Pre-oxygenation for 3 minutes
Number of subjects: 120
Study 37395586 — intervention group
Group type: EXPERIMENTAL
Intervention: Culprit lesions (CL) with coronary microevaginations (CMEs)
Number of subjects: 557
Study 37395586 — intervention group
Group type: EXPERIMENTAL
Intervention: Culprit lesions (CL) with intact fibrous cap (IFC) ACS
Number of subjects: 557
Study 37395586 — intervention group
Group type: EXPERIMENTAL
Intervention: IFC-ICB (intact fibrous cap with no coronary bifurcation)
Number of subjects: 557
Study 37395586 — intervention group
Group type: EXPERIMENTAL
Intervention: IFC-ICB
Number of subjects: 557
Study 37395586 — intervention group
Group type: EXPERIMENTAL
Intervention: Culprit blood analysis in IFC-ICB
Number of subjects: 557
Study 37395586 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirated culprit thrombi in IFC-ICB
Number of subjects: 557
Study 37395586 — intervention group
Group type: EXPERIMENTAL
Intervention: IFC-ACB (intact fibrous cap with association to a coronary bifurcation)
Number of subjects: 557
Study 37395600 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive-behavioural guided self-help (CBT-GSH)
Number of subjects: 271
Study 37395600 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive-analytic guided self-help (CAT-GSH)
Number of subjects: 271
Study 37395780 — intervention group
Group type: EXPERIMENTAL
Intervention: Decompression surgery alone
Number of subjects: 988
Study 37395780 — intervention group
Group type: COMPARATOR
Intervention: Decompression with instrumented fusion
Number of subjects: 988
Study 37395780 — intervention group
Group type: EXPERIMENTAL
Intervention: Natural course of LSS without planned surgical treatment
Number of subjects: 988
Study 37395806 — intervention group
Group type: EXPERIMENTAL
Intervention: Robotic distal gastrectomy (RDG)
Number of subjects: 449
Study 37395806 — intervention group
Group type: COMPARATOR
Intervention: Laparoscopic distal gastrectomy (LDG)
Number of subjects: 449
Study 37395806 — intervention group
Group type: COMPARATOR
Intervention: Open distal gastrectomy (ODG)
Number of subjects: 449
Study 37395841 — intervention group
Group type: EXPERIMENTAL
Intervention: Mindfulness-based therapy
Number of subjects: 70
Study 37395841 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 70
Study 37395948 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasound-guided dextrose hydrodissection (1 mL of 50% dextrose, 4 mL of 1% lidocaine, and 5 mL of 1% normal saline)
Number of subjects: 40
Study 37395948 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasound-guided dextrose hydrodissection
Number of subjects: 40
Study 37395948 — intervention group
Group type: COMPARATOR
Intervention: Ultrasonography
Number of subjects: 40
Study 37395974 — intervention group
Group type: EXPERIMENTAL
Intervention: Amlodipine, Losartan, Rosuvastatin, and Ezetimibe (A/L/R/E)
Number of subjects: 145
Study 37395974 — intervention group
Group type: COMPARATOR
Intervention: Amlodipine and Losartan (A/L)
Number of subjects: 145
Study 37395974 — intervention group
Group type: COMPARATOR
Intervention: Losartan, Rosuvastatin, and Ezetimibe (L/R/E)
Number of subjects: 145
Study 37396126 — intervention group
Group type: EXPERIMENTAL
Intervention: Innovative synbiotics treatment for CKD patients
Number of subjects: 0
Study 37396126 — intervention group
Group type: COMPARATOR
Intervention: Placebo (control group)
Number of subjects: 0
Study 37396307 — intervention group
Group type: EXPERIMENTAL
Intervention: Entecavir treatment for 78 weeks
Number of subjects: 394
Study 37396569 — intervention group
Group type: EXPERIMENTAL
Intervention: Willingness to facilitate abortion care in eight hypothetical scenarios
Number of subjects: 279
Study 37396569 — intervention group
Group type: EXPERIMENTAL
Intervention: Facilitation of abortion care in the last 30 days
Number of subjects: 279
Study 37396569 — intervention group
Group type: EXPERIMENTAL
Intervention: Obstruction of abortion care in the last 30 days
Number of subjects: 279
Study 37396569 — intervention group
Group type: EXPERIMENTAL
Intervention: Association between stigma (SABAS score) and willingness to facilitate abortion care
Number of subjects: 279
Study 37396569 — intervention group
Group type: EXPERIMENTAL
Intervention: Association between stigma (SABAS score) and obstruction of abortion care
Number of subjects: 279
Study 37396586 — intervention group
Group type: EXPERIMENTAL
Intervention: 3-dimensional (3D) printing technology for preoperative planning and guidance
Number of subjects: 1
Study 37396586 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative evaluation and guidance using 3D printing
Number of subjects: 1
Study 37396590 — intervention group
Group type: EXPERIMENTAL
Intervention: Immediate stenting
Number of subjects: 123
Study 37396590 — intervention group
Group type: EXPERIMENTAL
Intervention: Delayed stenting
Number of subjects: 123
Study 37396805 — intervention group
Group type: EXPERIMENTAL
Intervention: B244 OD 5.0
Number of subjects: 547
Study 37396805 — intervention group
Group type: EXPERIMENTAL
Intervention: B244 OD 20.0
Number of subjects: 547
Study 37396805 — intervention group
Group type: COMPARATOR
Intervention: Placebo (vehicle)
Number of subjects: 547
Study 37396808 — intervention group
Group type: EXPERIMENTAL
Intervention: CNM-Au8 (30 mg daily for 36 weeks)
Number of subjects: 45
Study 37396808 — intervention group
Group type: COMPARATOR
Intervention: Placebo (matching placebo daily for 36 weeks)
Number of subjects: 45
Study 37396963 — intervention group
Group type: EXPERIMENTAL
Intervention: MLMC obesity intervention
Number of subjects: 6
Study 37396963 — intervention group
Group type: COMPARATOR
Intervention: Comparison communities
Number of subjects: 6
Study 37397078 — intervention group
Group type: EXPERIMENTAL
Intervention: Remote Ischemic Conditioning (RIC) - 3 cycles of 5-minute inflation of a blood pressure cuff to 15 mm Hg above systolic pressure before anthracycline therapy
Number of subjects: 68
Study 37397078 — intervention group
Group type: COMPARATOR
Intervention: Sham intervention
Number of subjects: 68
Study 37397080 — intervention group
Group type: EXPERIMENTAL
Intervention: Remote Ischemic Conditioning (RIC)
Number of subjects: 55
Study 37397080 — intervention group
Group type: COMPARATOR
Intervention: Sham control
Number of subjects: 55
Study 37397318 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical fitness (PF)
Number of subjects: 490
Study 37397433 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychosocial intervention
Number of subjects: 77
Study 37397433 — intervention group
Group type: EXPERIMENTAL
Intervention: Integrated pharmaceutical care at psychosocial intervention
Number of subjects: 77
Study 37397433 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 77
Study 37397983 — intervention group
Group type: EXPERIMENTAL
Intervention: PPM-guided dosing of tacrolimus
Number of subjects: 62
Study 37397983 — intervention group
Group type: COMPARATOR
Intervention: Standard-of-care (SOC) clinician-determined dosing of tacrolimus
Number of subjects: 62
Study 37397985 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 μM simvastatin
Number of subjects: 426
Study 37397985 — intervention group
Group type: COMPARATOR
Intervention: Control (no treatment)
Number of subjects: 426
Study 37398014 — intervention group
Group type: EXPERIMENTAL
Intervention: Transdiagnostic Intervention for Sleep and Circadian Dysfunction (TranS-C) delivered by Generation 2 providers
Number of subjects: 9
Study 37398043 — intervention group
Group type: EXPERIMENTAL
Intervention: hrHPV detection (Xpert HPV, Cepheid)
Number of subjects: 371
Study 37398043 — intervention group
Group type: EXPERIMENTAL
Intervention: Portable colposcopy (Gynocular, Gynius)
Number of subjects: 371
Study 37398043 — intervention group
Group type: EXPERIMENTAL
Intervention: Visual inspection with acetic acid (VIA)
Number of subjects: 371
Study 37398043 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of hrHPV testing followed by Gynocular
Number of subjects: 371
Study 37398079 — intervention group
Group type: EXPERIMENTAL
Intervention: FDRs with pathogenic or likely pathogenic (P/LP) variants (n=39)
Number of subjects: 124
Study 37398079 — intervention group
Group type: EXPERIMENTAL
Intervention: FDRs with variants of uncertain significance (VUSs) (n=27)
Number of subjects: 124
Study 37398079 — intervention group
Group type: EXPERIMENTAL
Intervention: Negative FDRs of probands without P/LP variants (n=30)
Number of subjects: 124
Study 37398079 — intervention group
Group type: COMPARATOR
Intervention: Negative FDRs of probands with pathogenic or likely pathogenic (P/LP) variants (n=28)
Number of subjects: 124
Study 37398344 — intervention group
Group type: EXPERIMENTAL
Intervention: 1Hz rTMS
Number of subjects: 60
Study 37398344 — intervention group
Group type: EXPERIMENTAL
Intervention: cTBS
Number of subjects: 60
Study 37398344 — intervention group
Group type: COMPARATOR
Intervention: Sham
Number of subjects: 60
Study 37398344 — intervention group
Group type: EXPERIMENTAL
Intervention: Optimal TMS regimen (to be determined in Phase 1)
Number of subjects: 60
Study 37398344 — intervention group
Group type: COMPARATOR
Intervention: Sham (Phase 2)
Number of subjects: 60
Study 37398401 — intervention group
Group type: EXPERIMENTAL
Intervention: Interactive online training modules
Number of subjects: 82
Study 37398623 — intervention group
Group type: EXPERIMENTAL
Intervention: Elagolix 25 mg twice daily
Number of subjects: 114
Study 37398623 — intervention group
Group type: EXPERIMENTAL
Intervention: Elagolix 50 mg once daily
Number of subjects: 114
Study 37398623 — intervention group
Group type: EXPERIMENTAL
Intervention: Elagolix 75 mg twice daily
Number of subjects: 114
Study 37398623 — intervention group
Group type: EXPERIMENTAL
Intervention: Elagolix 150 mg once daily
Number of subjects: 114
Study 37398623 — intervention group
Group type: EXPERIMENTAL
Intervention: Elagolix 300 mg twice daily
Number of subjects: 114
Study 37398623 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 114
Study 37398623 — intervention group
Group type: EXPERIMENTAL
Intervention: Elagolix (all doses)
Number of subjects: 114
Study 37398685 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium zirconium cyclosilicate (SZC)
Number of subjects: 0
Study 37398685 — intervention group
Group type: COMPARATOR
Intervention: Standard of Care (SoC)
Number of subjects: 0
Study 37398686 — intervention group
Group type: EXPERIMENTAL
Intervention: Pre-transplantation risk assessment tool for graft survival
Number of subjects: 1428
Study 37398992 — intervention group
Group type: EXPERIMENTAL
Intervention: Ganitumab 18 mg/kg intravenously every 2 weeks and Dasatinib 60 mg/m2/dose (max 100 mg) oral once daily (DL1)
Number of subjects: 13
Study 37398992 — intervention group
Group type: EXPERIMENTAL
Intervention: Ganitumab 18 mg/kg intravenously every 2 weeks and Dasatinib 60 mg/m2/dose (max 70 mg) twice daily (DL2)
Number of subjects: 13
Study 37398992 — intervention group
Group type: EXPERIMENTAL
Intervention: Ganitumab 18 mg/kg every 2 weeks and Dasatinib 60 mg/m2/dose daily
Number of subjects: 13
Study 37399002 — intervention group
Group type: EXPERIMENTAL
Intervention: FODMAPs
Number of subjects: 0
Study 37399002 — intervention group
Group type: EXPERIMENTAL
Intervention: Gluten
Number of subjects: 0
Study 37399002 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 0
Study 37399009 — intervention group
Group type: EXPERIMENTAL
Intervention: NIPPV
Number of subjects: 1137
Study 37399009 — intervention group
Group type: EXPERIMENTAL
Intervention: NHFOV
Number of subjects: 1137
Study 37399009 — intervention group
Group type: COMPARATOR
Intervention: NCPAP
Number of subjects: 1137
Study 37399011 — intervention group
Group type: EXPERIMENTAL
Intervention: Stroke Ready intervention (combined ED and community components)
Number of subjects: 5970
Study 37399011 — intervention group
Group type: EXPERIMENTAL
Intervention: ED component of the Stroke Ready intervention
Number of subjects: 5970
Study 37399011 — intervention group
Group type: EXPERIMENTAL
Intervention: Community component of the Stroke Ready intervention
Number of subjects: 5970
Study 37399054 — intervention group
Group type: EXPERIMENTAL
Intervention: TeNDER system
Number of subjects: 534
Study 37399054 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 534
Study 37399056 — intervention group
Group type: EXPERIMENTAL
Intervention: Kelaa Mental Resilience app for 4 weeks
Number of subjects: 532
Study 37399066 — intervention group
Group type: EXPERIMENTAL
Intervention: eHealth care (remote patient monitoring and teleconsultation)
Number of subjects: 40
Study 37399066 — intervention group
Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 40
Study 37399099 — intervention group
Group type: EXPERIMENTAL
Intervention: Highest quartiles of CCL19
Number of subjects: 4483
Study 37399099 — intervention group
Group type: EXPERIMENTAL
Intervention: Highest quartiles of CCL21
Number of subjects: 4483
Study 37399099 — intervention group
Group type: EXPERIMENTAL
Intervention: CCL19 and CCL21 added to conventional risk factors
Number of subjects: 4483
Study 37399099 — intervention group
Group type: EXPERIMENTAL
Intervention: Major disability, death, and composite outcome of death or cardiovascular events
Number of subjects: 4483
Study 37399108 — intervention group
Group type: EXPERIMENTAL
Intervention: Telitacicept 160 mg
Number of subjects: 42
Study 37399108 — intervention group
Group type: EXPERIMENTAL
Intervention: Telitacicept 240 mg
Number of subjects: 42
Study 37399108 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 42
Study 37399287 — intervention group
Group type: EXPERIMENTAL
Intervention: psy-RBD-FDRs
Number of subjects: 0
Study 37399287 — intervention group
Group type: COMPARATOR
Intervention: psychiatric controls
Number of subjects: 0
Study 37399355 — intervention group
Group type: EXPERIMENTAL
Intervention: APRIL CAR
Number of subjects: 11
Study 37399357 — intervention group
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Number of subjects: 274
Study 37399357 — intervention group
Group type: COMPARATOR
Intervention: Paclitaxel
Number of subjects: 274
Study 37399447 — intervention group
Group type: EXPERIMENTAL
Intervention: Four different accommodation strategy components to compensate for cognitive dysfunction
Number of subjects: 256
Study 37399456 — intervention group
Group type: EXPERIMENTAL
Intervention: Defibrotide (6.25 mg/kg)
Number of subjects: 20
Study 37399671 — intervention group
Group type: EXPERIMENTAL
Intervention: Wellness intervention (diet, stress reduction techniques, sleep hygiene, and exercise) delivered via a 7-week web-based program
Number of subjects: 100
Study 37399671 — intervention group
Group type: COMPARATOR
Intervention: Waitlist control (WLC) group
Number of subjects: 100
Study 37399757 — intervention group
Group type: EXPERIMENTAL
Intervention: D-cycloserine (DCS) augmentation of exposure-based CBT
Number of subjects: 59
Study 37399757 — intervention group
Group type: COMPARATOR
Intervention: Exposure-based CBT without DCS augmentation
Number of subjects: 59
Study 37400140 — intervention group
Group type: EXPERIMENTAL
Intervention: Minimally Invasive Ponto Surgery (MIPS)
Number of subjects: 0
Study 37400140 — intervention group
Group type: COMPARATOR
Intervention: Linear incision technique with tissue preservation (LITT-P)
Number of subjects: 0
Study 37400140 — intervention group
Group type: EXPERIMENTAL
Intervention: MIPS
Number of subjects: 0
Study 37400140 — intervention group
Group type: COMPARATOR
Intervention: LITT-P
Number of subjects: 0
Study 37400162 — intervention group
Group type: EXPERIMENTAL
Intervention: Huachansu-TACE
Number of subjects: 120
Study 37400162 — intervention group
Group type: COMPARATOR
Intervention: TACE
Number of subjects: 120
Study 37400162 — intervention group
Group type: EXPERIMENTAL
Intervention: NKA-low group
Number of subjects: 120
Study 37400162 — intervention group
Group type: EXPERIMENTAL
Intervention: NKA-high group
Number of subjects: 120
Study 37400234 — intervention group
Group type: EXPERIMENTAL
Intervention: Bariatric surgery
Number of subjects: 0
Study 37400239 — intervention group
Group type: EXPERIMENTAL
Intervention: Customised insole with retrocapital bar and infracapital bar of the first metatarsal
Number of subjects: 80
Study 37400239 — intervention group
Group type: COMPARATOR
Intervention: Sham insole
Number of subjects: 80
Study 37400307 — intervention group
Group type: EXPERIMENTAL
Intervention: Dynamic computed tomography perfusion (CTP) analysis before and after successful CTO PCI
Number of subjects: 27
Study 37400353 — intervention group
Group type: EXPERIMENTAL
Intervention: Bacillus Calmette-Guérin (BCG) therapy
Number of subjects: 0
Study 37400353 — intervention group
Group type: EXPERIMENTAL
Intervention: Tumor molecular subtypes
Number of subjects: 0
Study 37400432 — intervention group
Group type: EXPERIMENTAL
Intervention: Stanford Neuromodulation Therapy (SNT)
Number of subjects: 24
Study 37400432 — intervention group
Group type: COMPARATOR
Intervention: Sham stimulation
Number of subjects: 24
Study 37400554 — intervention group
Group type: EXPERIMENTAL
Intervention: Whole-genome sequencing (WGS)
Number of subjects: 91
Study 37400554 — intervention group
Group type: EXPERIMENTAL
Intervention: RNA sequencing (RNA-Seq)
Number of subjects: 91
Study 37400554 — intervention group
Group type: EXPERIMENTAL
Intervention: WGS and RNA-Seq
Number of subjects: 91
Study 37400561 — intervention group
Group type: EXPERIMENTAL
Intervention: Home phototherapy
Number of subjects: 0
Study 37400561 — intervention group
Group type: COMPARATOR
Intervention: Hospital phototherapy
Number of subjects: 0
Study 37400681 — intervention group
Group type: EXPERIMENTAL
Intervention: Ixekizumab (IXE)
Number of subjects: 0
Study 37400753 — intervention group
Group type: EXPERIMENTAL
Intervention: Multi-biomarker test (MBT)
Number of subjects: 300
Study 37400753 — intervention group
Group type: EXPERIMENTAL
Intervention: Xpert® TB Fingerstick cartridge
Number of subjects: 300
Study 37400753 — intervention group
Group type: COMPARATOR
Intervention: Gold-standard composite TB outcome classification
Number of subjects: 300
Study 37400758 — intervention group
Group type: EXPERIMENTAL
Intervention: Pharmacist-led deprescribing intervention (education of health care personnel, access to standardized discontinuation regimens, patient education, support of transitional care)
Number of subjects: 173
Study 37400758 — intervention group
Group type: COMPARATOR
Intervention: Usual care (control group)
Number of subjects: 173
Study 37400758 — intervention group
Group type: EXPERIMENTAL
Intervention: Pharmacist-led intervention
Number of subjects: 173
Study 37400771 — intervention group
Group type: EXPERIMENTAL
Intervention: Carbohydrate-rich dietary pattern
Number of subjects: 140
Study 37400771 — intervention group
Group type: EXPERIMENTAL
Intervention: Protein-rich dietary pattern
Number of subjects: 140
Study 37400771 — intervention group
Group type: EXPERIMENTAL
Intervention: Unsaturated fat-rich dietary pattern
Number of subjects: 140
Study 37400771 — intervention group
Group type: EXPERIMENTAL
Intervention: Diet-related proteins
Number of subjects: 140
Study 37400771 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall association
Number of subjects: 140
Study 37400771 — intervention group
Group type: COMPARATOR
Intervention: ARIC study
Number of subjects: 140
Study 37400806 — intervention group
Group type: EXPERIMENTAL
Intervention: Circulating DNA (cDNA) detection before potentiated radiotherapy and at 3 months post-treatment.
Number of subjects: 32
Study 37400812 — intervention group
Group type: EXPERIMENTAL
Intervention: Saccharomyces boulardii (Sb) 600 mg orally once daily for eight days
Number of subjects: 46
Study 37400812 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 46
Study 37400828 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 Hz rTMS
Number of subjects: 120
Study 37400828 — intervention group
Group type: EXPERIMENTAL
Intervention: cTBS
Number of subjects: 120
Study 37400828 — intervention group
Group type: COMPARATOR
Intervention: Sham TMS
Number of subjects: 120
Study 37400828 — intervention group
Group type: EXPERIMENTAL
Intervention: Optimal TMS regimen (to be determined in phase 1)
Number of subjects: 120